

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

VACCINES FOR CHILDREN PROGRAM

VACCINES TO PREVENT PNEUMOCOCCAL DISEASE

The purpose of this resolution is to update recommendations regarding the use of pneumococcal conjugate vaccines (PCV) for children to include 20-valent PCV (PCV20) as an option.

VFC resolution 06/22-1 is repealed and replaced by the following:

A. Pneumococcal Conjugate Vaccine (PCV) to Prevent Pneumococcal Disease

Eligible groups

- *All children six weeks through 59 months of age*
- *Children 5 through 18 years of age with certain underlying medical conditions that increase the risk of pneumococcal disease (hereafter, risk conditions) listed in Table 1*

Table 1. Risk conditions that are indications for pneumococcal vaccination among children

Chronic medical conditions	Chronic heart disease*
	Chronic kidney disease (excluding maintenance dialysis and nephrotic syndrome, which are included in immunocompromising conditions)
	Chronic liver disease
	Chronic lung disease (including moderate persistent or severe persistent asthma)
	Diabetes mellitus
	Cerebrospinal fluid leak
	Cochlear implant
Immunocompromising conditions	Sickle cell disease and other hemoglobinopathies
	Congenital or acquired asplenia, or splenic dysfunction
	HIV infection
	On maintenance dialysis or nephrotic syndrome
	Diseases associated with immunosuppressive chemotherapy, or radiation therapy including malignant neoplasms, leukemias, lymphomas and Hodgkin disease; or solid organ transplantation
	Congenital or acquired immunodeficiency**
* Particularly cyanotic congenital heart disease and cardiac failure	
** Includes B- (humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease)	

Recommended Vaccine Schedule and Dosage Intervals

Table 2. Recommended schedules for administering doses of either 15-valent PCV (PCV15) or PCV20 among children who have not previously received PCV, and those incompletely vaccinated with PCV for age.

Age	Vaccination history: total number of PCV doses received previously	Recommended PCV Regimen^{1,2,3}
2–6 mo	0 doses	3 doses, 8 weeks apart; fourth dose at age 12–15 mos
	1 dose	2 doses, 8 weeks apart; fourth dose at age 12–15 mos
	2 doses	1 dose, 8 weeks after the most recent dose; fourth dose at age 12–15 mos
7–11mo	0 doses	2 doses, 8 weeks apart; third dose at 12–15 mos
	1 or 2 doses before age 7 mo	1 dose at age 7–11 mos; second dose at 12–15 mos (≥ 8 weeks later)
12–23 mo	0 doses	2 doses, ≥ 8 weeks apart
	1 dose before age 12 mo	2 doses, ≥ 8 weeks apart
	1 dose at ≥ 12 mo	1 dose, ≥ 8 weeks after the most recent dose
	2 or 3 doses before age 12 mo	1 dose, ≥ 8 weeks after the most recent dose
24–59 mo		
Healthy children	Any incomplete schedule	1 dose, ≥ 8 weeks after the most recent dose
24–71 mo		
Children with risk conditions as defined in Table 1 ⁴	Any incomplete schedule of ≤ 2 doses ⁵	2 doses, one ≥ 8 weeks after the most recent dose and another dose ≥ 8 weeks later
	3 doses, all given < 12 months	1 dose, ≥ 8 weeks after the most recent dose
6–18 years		
Children with risk conditions as defined in Table 1 ⁴	0 doses	1 dose ⁶

Table notes:

- 1) Either PCV15 or PCV20 may be used for the full series or to complete the recommended schedule begun with PCV13.
- 2) If only 13-valent PCV (PCV13) is available when the child is scheduled to receive a PCV, PCV13 may be given as previously recommended.
- 3) Minimum interval between doses is 8 weeks except for children vaccinated at age <1 year, for whom minimum interval between doses is 4 weeks.
- 4) For children with risk conditions (see Table 1), either PCV15 or PCV20 is indicated through 18 years of age.
- 5) If a child received 2 doses of PCV between 12–23 months, the child has received a complete PCV schedule even though the total number of PCV doses received is 2.
- 6) When PCV15 is used, it should be followed by a dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) ≥ 8 weeks after the PCV15 dose if not previously given.

Recommended dosage

Refer to product package inserts.

Contraindications and Precautions

Contraindications and precautions can be found at: [Vaccines Licensed for Use in the United States | FDA](#)

B. Pneumococcal Polysaccharide Vaccine (PPSV23) to Prevent Pneumococcal Disease**Eligible groups**

- *Children aged 2 through 18 years with any risk condition as defined in Table 1*

Recommended Vaccine Schedule and Dosage Intervals

See Table 2 (footnote 6) for children 2–18 years of age who received the recommended PCV dose at age ≥ 6 years.

Table 3. Schedule for vaccination for children 2–18 years of age with risk conditions** who have completed their recommended PCV doses before age 6 years.

Group	Schedule for PCV20 or PPSV23*	Vaccination with PCV20 or Revaccination with PPSV23
Children with risk conditions who have received ≥ 1 dose of PCV20	Not indicated	Not indicated
Children with chronic medical conditions** who have not received PCV20	1 dose of PCV20 or PPSV23 administered at age ≥ 2 yrs, ≥ 8 weeks after last indicated dose of PCV	Not indicated

Children with an immunocompromising condition** who have not received PCV20 (option1)	1 dose of PCV20	Not indicated
Children with an immunocompromising condition** who have not received PCV20 (option2)	1 dose of PPSV23 administered at age ≥ 2 yrs, ≥ 8 weeks after last indicated dose of PCV	1 dose of PCV20 5 years after the first dose of PPSV23
Children with an immunocompromising condition** who have not received PCV20 (option3)	1 dose of PPSV23 administered at age ≥ 2 yrs, ≥ 8 weeks after last indicated dose of PCV	1 dose PPSV23 5 years after the first dose of PPSV23

*Doses of PCV should be completed before PPSV23 is given. No more than two PPSV23 doses are recommended.

**See Table 1 for definitions of chronic medical and immunocompromising conditions.

Recommended dosage

Refer to product package inserts.

Contraindications and Precautions

Contraindications and precautions can be found at: [Vaccines Licensed for Use in the United States | FDA](#)

[If an ACIP recommendation regarding pneumococcal vaccination is published within 12 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the publication URL.]

Adopted and Effective: June 22, 2023

This document can be found on the CDC website at:
<https://www.cdc.gov/vaccines-for-children/hcp/vaccines-provided/>